newsfilter
← Latest News
GlobeNewswire·

CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

  • CalciMedica, Inc. (NASDAQ: CALC) will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026.
  • The company is developing calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory, immunologic, & cardiopulmonary diseases.
  • The pipeline includes zegocractin (Auxora™), formulated for intravenous administration, & CM5480, designed for chronic oral dosing.
  • Auxora has been evaluated in over 350 patients & is being developed for pulmonary arterial hypertension & acute pancreatitis.
  • A Phase 1b proof-of-concept trial in pulmonary arterial hypertension & a Phase 2b trial in acute pancreatitis are planned for Auxora.
  • CM5480 is being developed for pulmonary hypertension, with an IND submission anticipated in mid-2027.
  • Joyce Allaire of LifeSci Advisors, LLC serves as the Investor Relations contact for CalciMedica.